| Previous Close | 1.38 |
| Open | 1.4 |
| Day High | 1.51 |
| Day Low | 1.39 |
| 52-Week High | 3.54 |
| 52-Week Low | 0.76 |
| Volume | 442,539 |
| Average Volume | 597,161 |
| Market Cap | 90.04M |
| PE | -7.1 |
| EPS | -0.2 |
| Moving Average 50 Days | 1.9 |
| Moving Average 200 Days | 2.07 |
| Change | 0.04 |
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Feb 25, 2026 1:30 PM GMT
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fire
Equillium to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory diso
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation